newsfilter
← Latest News
Business Wire·

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Strategic merger with Rafael Holdings to combine two companies and advance Trappsol® Cyclo™ for NPC1 patients expected to close Q4 2024 Company on track for topline data from the 48-week interim analysis